Gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction-overlapping conditions that affect asthma.

Autor: Eapen AA; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Henry Ford Health + Michigan State University, Detroit, Mich., Gupta MR; Division Immunology, Allergy, and Retrovirology, Texas Children's Hospital and Baylor College of Medicine, Houston, Tex., Lockey RF; Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Fla., Bardin PG; Monash Lung Sleep Allergy & Immunology, Melbourne, Australia; Hudson Institute, Melbourne, Australia; Monash Hospital and University, Melbourne, Australia., Baptist AP; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Henry Ford Health + Michigan State University, Detroit, Mich. Electronic address: abaptis1@hfhs.org.
Jazyk: angličtina
Zdroj: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Dec; Vol. 154 (6), pp. 1369-1377. Date of Electronic Publication: 2024 Oct 18.
DOI: 10.1016/j.jaci.2024.10.006
Abstrakt: Asthma is a chronic lung condition that may be affected by numerous medical comorbidities. Such comorbidities can influence the presentation and even the severity of asthma. Alternatively, asthma may be misdiagnosed as a comorbidity when symptoms overlap. The 3 medical conditions that commonly affect asthma management are gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction). These conditions can be difficult to distinguish from one another, as well as from asthma itself. In this review, the epidemiology, pathophysiology, symptomatology, and diagnostic considerations of each condition in both adult and pediatric populations are discussed. Treatment options, as well as how such options may influence asthma outcomes, are included. Finally, knowledge gaps in each area are highlighted, as a better understanding of the optimal diagnostic and therapeutic approaches will allow for improved individualized care of patients with asthma.
Competing Interests: Disclosure statement Supported by NIH grant R01NR019566 to A.P.B. Disclosure of potential conflict of interest: M. R. Gupta reports serving as a consultant to AstraZeneca, Sanofi-Regeneron, and Incyte Corporation. P. G. Bardin reports performing research for the National Health and Medical Research Council, Australia, and serving as a consultant to AstraZeneca, GSK, Sanofi, and Chiesi. A. P. Baptist reports performing research for GSK, AstraZeneca, Regeneron, and the American Lung Association and serving as a consultant to GSK, AstraZeneca, Regeneron, and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.
(Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: